Sign up
Pharma Capital

LexaGene Holdings completes development of Antibiotic Resistance Panel

LexaGene Holdings (CVE:LXG-OTCQB:LXXGF) Co-Founder and CEO Dr Jack Regan joined Steve Darling from the Toronto studio of Proactive Investors to discuss their announcement dealing with antibiotic resistance.

Regan tells Proactive why this is needed and which industries they will be the only player in the market dealing with this.


View full LXG profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.